Fillers
POEM
Harms outweigh benefits of COX 2 for many patients
BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7389.0/f (Published 15 March 2003) Cite this as: BMJ 2003;326:fQuestion How safe are COX 2 inhibitors?
Synopsis This is an excellent (although non-systematic) review of the benefits and harms of COX 2 inhibitors. It is non-systematic because we aren't given details of the author's search strategy or inclusion criteria, and he only really discusses the two large COX 2 trials (VIGOR for rofecoxib and CLASS for celecoxib). Nevertheless, these two studies are the 800 pound gorillas in this area, and the author took advantage of …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.